Abstract
In a randomized, double-blind, crossover study, we evaluated the effect of intravenous lidocaine (5 mg/kg body weight over 30 min) on the neuropathic pain of advanced cancer patients. Pain intensity, assessed by a visual analogue scale, did not show any significant difference between lidocaine and placebo infusion. The blinded choice of patients and investigators also suggested no significant improvement from lidocaine when given by this regimen. Intravenous lidocaine does not appear to have a significant analgesic effect on neuropathic cancer pain.
| Original language | English |
|---|---|
| Pages (from-to) | 138-140 |
| Number of pages | 3 |
| Journal | Journal of Pain and Symptom Management |
| Volume | 7 |
| Issue number | 3 |
| Publication status | Published - 1992 |
Fingerprint
ASJC Scopus subject areas
- Anesthesiology and Pain Medicine
Cite this
Bruera, E., Ripamonti, C., Brenneis, C., Macmillan, K., & Hanson, J. (1992). A randomized double-blind crossover trial of intravenous lidocaine in the treatment of neuropathic cancer pain. Journal of Pain and Symptom Management, 7(3), 138-140.